A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer

被引:93
作者
Cree, Ian A. [1 ]
Kurbacher, Christian M.
Lamont, Alan
Hindley, Andrew C.
Love, Sharon
机构
[1] Queen Alexandra Hosp, Translat Oncol Res Ctr, Portsmouth PO9 6AH, Hants, England
[2] Southend Hosp, Dept Radiotherapy & Oncol, Westcliff On Sea, Essex, England
[3] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
[4] Wolfson Coll Annexe, Ctr Stat Med, Oxford, England
[5] Med Ctr Bonn, Bonn, Germany
关键词
aTP-based tumour chemosensitivity assay; chemosensitivity; crossover; ovarian; platinum; predictive; randomized trial; resistance;
D O I
10.1097/CAD.0b013e3281de727e
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice. A total of 180 patients were randomized to assay-directed therapy (n=94) or physician's-choice chemotherapy (n=86). Median follow-up at analysis was 18 months. Response was assessable in 147 patients: 31.5% achieved a partial or complete response in the physician's-choice group compared with 40.5% in the assay-directed group (26 versus 31% by intention-to-treat analysis respectively). Intention-to-treat analysis showed a median progression-free survival of 93 days in the physician's-choice group and 104 days in the assay-directed group (hazard ratio 0.8, 95% confidence interval 0.59-1.10, not significant). No difference was seen in overall survival between the groups, although 12/39 (41%) of patients who crossed over from the physician's-choice arm obtained a response. Increased use of combination therapy was seen in the physician's-choice arm during the study as a result of the observed effects of assay-directed therapy in patients. Patients entering the physician's-choice arm of the study during the first year did significantly worse than those who entered in the subsequent years (hazard ratio 0.44, 95% confidence interval 0.2-0.9, P < 0.03). This small randomized clinical trial has documented a trend towards improved response and progression-free survival for assay-directed treatment Chemosensitivity testing might provide useful information in some patients with ovarian cancer, although a larger trial is required to confirm this. The ATP-based tumour chemosensitivity assay remains an investigational method in this condition. (c) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:1093 / 1101
页数:9
相关论文
共 34 条
[1]  
ANDREOTTI PE, 1995, CANCER RES, V55, P5276
[2]   Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer [J].
Breidenbach, M ;
Rein, DT ;
Schöndorf, T ;
Schmidt, T ;
König, E ;
Valter, M ;
Kurbacher, CM .
ANTI-CANCER DRUGS, 2003, 14 (05) :341-346
[3]   Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment [J].
Breidenbach, M ;
Rein, DT ;
Mallmann, P ;
Kurbacher, CM .
ANTI-CANCER DRUGS, 2002, 13 (02) :173-176
[4]  
Coleman RL, 2002, ONCOLOGIST, V7, P46
[5]   Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial [J].
Crawford, SC ;
Vasey, PA ;
Paul, J ;
Hay, A ;
Davis, JA ;
Kaye, SB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8802-8811
[6]  
Cree IA, 2003, RECENT RES CANCER, V161, P119
[7]   Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity [J].
Cree, IA ;
Kurbacher, CM ;
Untch, M ;
Sutherland, LA ;
Hunter, EM ;
Subedi, AMC ;
James, EA ;
Dewar, JA ;
Preece, PE ;
Andreotti, PE ;
Bruckner, HW .
ANTI-CANCER DRUGS, 1996, 7 (06) :630-635
[8]   Individualizing chemotherapy for solid tumors - Is there any alternative? [J].
Cree, IA ;
Kurbacher, CM .
ANTI-CANCER DRUGS, 1997, 8 (06) :541-548
[9]  
Cree IA, 1998, METH MOL B, V102, P169
[10]  
Cree Ian A, 2002, Curr Opin Investig Drugs, V3, P634